Overview

Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine, methotrexate, leucovorin, and antithymocyte globulin before and after transplant may stop this from happening. It is not yet known which treatment regimen is most effective in treating acute leukemia. PURPOSE: This randomized clinical trial is studying how well different therapies work in treating infants with newly diagnosed acute leukemia.
Phase:
N/A
Details
Lead Sponsor:
Dutch Childhood Oncology Group
Collaborators:
Associazione Italiana Ematologia Oncologia Pediatrica
Australian and New Zealand Children's Oncology Group
BFM Austria
BFM Germany
CLCG France Belgium Portugal
COALL Germany
CORS Monza Italy
CPH, Czech republic
DFCI consortium USA
FRALLE France
Hong Kong
MD Anderson USA
NOPHO Scandinavian countries
PINDA, Chile
PPLLSG Poland
Seattle USA
SJCRH USA
UKCCSG United Kingdom
Treatments:
6-Mercaptopurine
Antilymphocyte Serum
Asparaginase
Busulfan
Cortisol succinate
Cyclophosphamide
Cyclosporine
Cyclosporins
Cytarabine
Daunorubicin
Etoposide
Hydrocortisone
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Hydrocortisone hemisuccinate
Leucovorin
Levoleucovorin
Melphalan
Mercaptopurine
Methotrexate
Mitoxantrone
Pegaspargase
Prednisolone
Prednisone
Thioguanine
Vincristine